Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis

Journal of Medical Economics

Volumn 16, Issue 6, 2013, Pages 801-808

  Nasr, Samya Z ^a   Chou, Will ^b   Villa, Kathleen F ^b   Chang, Eunice ^c   Broder, Michael S ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b GENENTECH INC   (United States)

^c PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

Author keywords

Cohort study; Cost; Insurance claims; Utilization

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; SODIUM CHLORIDE; STEROID; TOBRAMYCIN;

ADOLESCENT; ADULT; AGE; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; BILLING AND CLAIMS; CHILD; CHRONIC SINUSITIS; COHORT ANALYSIS; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; ECONOMIC EVALUATION; EMERGENCY WARD; FAILURE TO THRIVE; FALLING; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEDICATION COMPLIANCE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PANCREAS INSUFFICIENCY; PATIENT COMPLIANCE; PHARMACY; PRESCHOOL CHILD; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SCHOOL CHILD; SPRING; SUMMER; WINTER;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE COVERAGE; INSURANCE, HEALTH; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84878935910     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.787427     Document Type: Article

References (19)

1. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med 2007;176:957-69
2. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003
3. Pulmozyme-. (dornase alfa) [prescribing information]. South San Francisco, CA: Genentech, Inc., 2010
4. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
5. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
6. O'Malley AS, Pham HH, Schrag D, et al. Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics. Med Care 2007;45:562-70
7. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
8. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9
9. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82
10. Hwang W, Weller W, Ireys H, et al. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood) 2001;20:267-78
11. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-96
12. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011;10:258-64
13. Daniels T, Goodacre L, Sutton C, et al. Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers. Chest 2011;140:425-32
14. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004;125(Suppl 1):1S-39S
15. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-65
16. PriceRx, Wolters Kluwer Health. http://www.medispan.com/drug- pricinganalysis- pricerx.aspx. Accessed November 10, 2011
17. Cystic Fibrosis Foundation. Patient Registry. 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation, 2011
18. Krauth C, Jalilvand N, Welte T, et al. Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies. Pharmacoeconomics 2003;21:1001-24
19. Schechter MS, Shelton BJ, Margolis PA, et al. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001;163:1331-7